Fortis Healthcare FY24 Annual Earnings Summary
4 quarters covered · ₹6,893 Cr revenue · ₹645 Cr PAT · 18.4% average EBITDA margin.
Quarter-by-quarter progression
Management promises made during the year
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
Q2 FY24Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
Q2 FY24Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
Q3 FY24Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
Q4 FY24Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
Q4 FY24Risks flagged during the year
If PE investor exercises put option, Fortis may need to raise ~₹1,200-1,300 crore, potentially via debt or equity, impacting leverage or dilution.
Q1 FY24 · mediumManagement acknowledged industry-wide nursing shortage and wage inflation, which could pressure margins.
Q1 FY24 · mediumQ1 occupancy at 64% and higher government scheme mix impacted profitability; recovery depends on mix improvement.
Q2 FY24 · mediumElevated legal costs of INR 6-7 crore in Q2 due to ongoing litigation; timing of resolution is uncertain and could continue to pressure margins.
Q2 FY24 · mediumAnalyst raised concern about rising guaranteed payouts for clinicians; management acknowledged some churn but deemed risk low. However, cost pressures could impact margin trajectory.
Q2 FY24 · mediumManagement identified potential delays in brownfield bed commissioning as a key risk to achieving FY25 margin targets.
Q3 FY24 · mediumNew bed additions could dilute occupancy, delaying margin expansion. Management acknowledged this but expects gradual ramp-up.
Q3 FY24 · mediumFlat international revenue in Q3 due to Middle East tensions; recovery seen but risks remain from geopolitical instability.
Q3 FY24 · medium~950 beds in hospitals with <10% EBITDA margin; structural improvements like adding specialties will take 2-3 years.
Q3 FY24 · mediumFMRI Gurgaon saw a premium cardiac clinician depart, impacting Q3 performance. New clinician expected to join in Q4.
Q4 FY24 · mediumAnnual legal costs of ₹30-50 crore related to legacy issues (brand, forensic audit) may persist until resolution; Supreme Court stay on promoter shareholding dismissed.
Q4 FY24 · mediumAgilus volumes grew only 0.6% in Q4 despite rebranding; competitive pressures and government business provisions may delay margin recovery.
What changed through the year
Q1 FY24 · Hospital EBITDA margin target of 18-20%
Management reiterated guidance for hospital EBITDA margins to trend towards 18-20% in coming quarters, despite Q1 margin of 15.2%.
Q1 FY24 · ARPOB growth of 4-5% for FY24
Management expects ARPOB to grow 4-5% for the full year, moderating from Q1's 12% growth due to base effects.
Q1 FY24 · Occupancy to trend towards 70% over 2-3 years
Management expects occupancy to reach 70% over the medium term, supported by bed additions and ramp-up.
Q1 FY24 · Addition of ~1,400 beds over 2-3 years
Planned bed additions of 300-400 per year, primarily brownfield expansions in NCR, Mulund, and Kolkata.
Q2 FY24 · 20% hospital EBITDA margin by FY25
Management reiterated its target of achieving 20% EBITDA margin for the hospital business in the next financial year, driven by occupancy ramp-up and cost control.
Q2 FY24 · 70% occupancy exit rate in FY24
The company expects to exit FY24 with occupancy around 70%, despite seasonal fluctuations and new bed additions.
Q2 FY24 · 250 beds to be added in FY24
Brownfield expansions at Mulund, Anandapur, BG Road, and Ludhiana will add approximately 250 beds in the current financial year.
Q2 FY24 · 1,800 beds in pipeline over 3-4 years
Total brownfield bed pipeline increased to 1,800 beds, including new projects at Mohali (400 beds) and Shalimar Bagh, plus Manesar (350 beds) over 2.5-3 years.
Q3 FY24 · Hospital EBITDA margin target of 20% by end of FY24
Management expects to achieve 20% EBITDA margin for the hospital business by year-end, driven by occupancy improvement and cost optimization.
Q3 FY24 · Long-term hospital EBITDA margin target of 25% in 3-4 years
Over the next 3-4 years, as brownfield bed expansions ramp up, management aims for 25% EBITDA margin.
Q3 FY24 · ~2,200 brownfield beds over next 4 years
Brownfield bed expansion plan to add ~2,200 beds, with ~710 beds expected in FY25, including the Manesar acquisition.
Q3 FY24 · Occupancy expected to trend toward 70% in coming quarters
Management expects occupancy to recover to ~70% in Q4 FY24 and next year, driven by seasonal recovery and international patient rebound.
Q4 FY24 · FY25 EBITDA margin improvement of ~200bps YoY
Hospital operating EBITDA margin expected to improve by ~200bps in FY25, building on FY24's 18.6% (hospital) and 18.4% consolidated.
Q4 FY24 · Brownfield bed addition of ~700 beds in FY25
Includes 50 beds each at Faridabad and Kalyan, 100 beds at Manesar (Q2), 100 beds at Kolkata (Q1), and beds at BG Road (Q2).
Q4 FY24 · Medium-term ARPOB growth of 4-5%
ARPOB growth expected to moderate to 4-5% in medium term from 10.8% in FY24, driven by 2-2.5% price increases and case mix improvement.
Q4 FY24 · Agilus put option resolution by Q2 FY25
Management expects to finalize the put option (due Oct 2024) by August-September 2024, with options including IPO revival or buyout via debt/equity.